COSCIENS Biopharma Inc.
CSCIF
$4.98
-$0.32-6.04%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -101.88% | 592.76% | -20.01% | 32.65% | 26.10% |
| Total Depreciation and Amortization | -1.17% | 17.99% | 0.70% | 0.00% | -11.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 105.74% | -78,940.00% | 84.21% | -124.23% | 218.70% |
| Change in Net Operating Assets | 84.71% | -423.23% | -53.84% | 139.22% | -282.74% |
| Cash from Operations | 127.51% | -48.10% | -117.46% | 84.80% | -136.54% |
| Capital Expenditure | -300.00% | 95.65% | -- | -- | 92.03% |
| Sale of Property, Plant, and Equipment | -22.22% | -96.23% | 5,875.00% | 300.00% | -75.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -795.65% | -111.44% | 4,925.00% | 108.33% | 92.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 29.27% | -446.67% | 82.35% | -30.77% | 67.50% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29.27% | -446.67% | 82.35% | 20.56% | 46.50% |
| Foreign Exchange rate Adjustments | -210.00% | -129.85% | 228.85% | -129.38% | 195.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.86% | -89.15% | -50.43% | 81.72% | -67.93% |